Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases

E. Munzone, E. Botteri, A. Esposito, A. Sciandivasci, D. Franchi, G. Pruneri, N. Rotmensz, G. Curigliano, L. Adamoli, L. Bocciolone, A. Goldhirsch, F. Nolé

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Patients with metastatic breast cancer to the ovary, without tumor debulking and after systemic therapy, have a 5-year survival rate <10%. Patients and methods: We analyzed a series of 37 patients, operated in one institution over 10 years, for both the primary tumor (PT) and ovarian/pelvic metastases (OPM). Estrogen receptors (ER), progesterone receptors (PgR), HER-2 and Ki-67 were determined. Results: Patients were predominantly young: 27 (73%) patients were <50 years. Average ER/PgR expression did not change significantly between PT (mean ER = 66%, PgR = 35%) and OPM (mean ER = 67%, PgR = 28%). Median time to OPM was 42 months (range 0-176); 5-year OS after OPM was 51% (95% confidence interval 32% to 67%). When combining ER and PgR status, patients with ER > 50% on both PT and OPM and with PgR > 50% on PT and/or OPM (good prognosis, 11 patients) had a better outcome versus0 patients with ER and PgR ≤ 50% on both PT and OPM (bad prognosis, eight patients) and also versus the remaining patients (intermediate prognosis, 18 patients), P value = 0.010. Conclusion: Patients with OPM from breast cancer show a favorable prognosis after tumor debulking, whether it was radical or not, especially when a high expression of ER and PgR is present in both PT and OPM.

Original languageEnglish
Article numbermds098
Pages (from-to)2884-2890
Number of pages7
JournalAnnals of Oncology
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 2012

Keywords

  • Breast cancer
  • ER status
  • HER-2 overexpression
  • Ovarian metastases
  • PgR status
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases'. Together they form a unique fingerprint.

Cite this